Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy and Safety of Liraglutide Adjunct to Insulin Treatment in Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial~* Male or female, aged equal to or greater than 18 years at the time of signing informed consent~* Type 1 diabetes mellitus (as diagnosed clinically) 12 months or longer prior to Visit 1 (i.e. screening)~* Treatment with basal bolus or CSII (continuous subcutaneous insulin infusion, insulin pump) treatment 6 months or longer prior to Visit 1 (i.e. screening)~* Stable insulin treatment 3 months or longer prior to Visit 1 (i.e. screening), as judged and documented by the investigator~* HbA1c 7.0-10.0 percent (Diabetes Control and Complications Trial (DCCT)), both inclusive, by central laboratory analysis (Visit 1, screening) corresponding to 53-86 mmol/mol (International Federation of Clinical Chemistry (IFCC))~Exclusion Criteria:~* Prior use of glucagon-like peptide-1 (GLP-1) receptor agonist or dipeptidyl peptidase IV (DPPIV) inhibitors~* Use of any medication, which in the investigator's opinion could interfere with the glycaemic control (e.g. systemic corticosteroids, pramlintide (Symlin®)) or affect the subject's safety. Premix insulin is not allowed~* Known proliferative retinopathy or maculopathy requiring acute treatment~* Severe neuropathy, in particular autonomic neuropathy, i.e. gastroparesis, as judged by the investigator~* Uncontrolled/untreated blood pressure at screening (Visit 1) (after resting for 5 minutes) while sitting greater than 160 mmHg for systolic or greater than 100 mmHg for diastolic (repeated measurement at Visit 2 (prior to performing the trial related activities) is allowed to exclude white-coat hypertension)~* History of acute or chronic pancreatitis~* Screening (Visit 1) calcitonin value equal to or greater than 50 ng/L

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Liraglutide 1.8 mg + insulin (Type: EXPERIMENTAL): None
- Liraglutide 1.2 mg + insulin (Type: EXPERIMENTAL): None
- Liraglutide 0.6 mg + insulin (Type: EXPERIMENTAL): None
- Liraglutide placebo 0.3 ml + insulin (Type: PLACEBO_COMPARATOR): None
- Liraglutide placebo 0.2 ml + insulin (Type: PLACEBO_COMPARATOR): None
- Liraglutide placebo 0.1 ml + insulin (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).